Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection.

Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, Guiguet M, Porter K; CASCADE Collaboration in EuroCoord.

PLoS One. 2013 Nov 14;8(11):e78642. doi: 10.1371/journal.pone.0078642. eCollection 2013.

2.

Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.

Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, Amo JD, Johnson AM, Babiker A, Porter K; CASCADE Collaboration in EuroCoord.

Clin Infect Dis. 2011 Oct;53(8):817-25. doi: 10.1093/cid/cir494.

PMID:
21921225
4.

Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.

Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K; CASCADE Collaboration.

J Natl Cancer Inst. 2010 Jun 2;102(11):784-92. doi: 10.1093/jnci/djq134. Epub 2010 May 4.

5.

Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort.

Koegl C, Wolf E, Hanhoff N, Jessen H, Schewe K, Rausch M, Goelz J, Goetzenich A, Knechten H, Jaeger H, Becker W, Becker-Boost I, Berzow D, Beiniek B, Brust J, Shcuster D, Dupke S, Fenske S, Gellermann HJ, Gippert R, Hartmann P, Hintsche B, Jaeger H, Jaegel-Guedes E, Jessen H, Gölz J, Koelzsch J, Helm EB, Knecht G, Knechten H, Lochet I, Gute P, Mauruschat S, Mauss S, Miasnikov V, Mosthaf FA, Rausch M, Freiwald M, Reuter B, Schalk HM, Schappert B, Schnaitmann E, Schneider I, Schüler-Maué W, Schuler C, Seidel T, Starke W, Ulmer A, Müller M, Weitner I, Schewe K, Zamani C, Hanmond A, Ross K, Bottlaender A, Hoffmann C, Dix A, Schneidewind A, Lademann M; Ac-DAG Study Group.

Eur J Med Res. 2009 Jul 22;14(7):277-83.

6.

Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters.

Madec Y, Boufassa F, Porter K, Meyer L; CASCADE Collaboration.

AIDS. 2005 Nov 18;19(17):2001-7.

PMID:
16260907
7.

Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data.

Clements M, Law M, Pedersen C, Kaldor J; CASCADE Collaboration.

HIV Med. 2003 Oct;4(4):332-7.

8.

Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies.

eligibility for ART in lower income countries (eART-linc) collaboration, Wandel S, Egger M, Rangsin R, Nelson KE, Costello C, Lewden C, Lutalo T, Ndyanabo A, Todd J, Van der Paal L, Minga A, Zwahlen M.

Sex Transm Infect. 2008 Aug;84 Suppl 1:i31-i36. doi: 10.1136/sti.2008.029793.

9.

Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.

Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, Chêne G, Mussini C, Porter K, Bucher HC; CASCADE Collaboration Members.

PLoS Med. 2010 Feb 23;7(2):e1000239. doi: 10.1371/journal.pmed.1000239.

11.

The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK.

Inshaw J, Leen C, Fisher M, Gilson R, Hawkins D, Collins S, Fox J, McLean K, Fidler S, Phillips A, Lattimore S, Babiker A, Porter K; UK HIV Seroconverters Cohort.

PLoS One. 2015 Jul 30;10(7):e0132772. doi: 10.1371/journal.pone.0132772. eCollection 2015.

13.

Predictors of disease progression in HIV-infected homosexual men with CD4+ cells < 200 x 10(6)/l but free of AIDS-defining clinical disease.

Keet IP, Krol A, Koot M, Roos MT, de Wolf F, Miedema F, Coutinho RA.

AIDS. 1994 Nov;8(11):1577-83.

PMID:
7848594
15.

Risk of tuberculosis following HIV seroconversion in high-income countries.

Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E; CASCADE collaboration in EuroCoord.

Thorax. 2013 Mar;68(3):207-13. doi: 10.1136/thoraxjnl-2012-201740. Epub 2012 Oct 31.

16.

Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS.

Maas JJ, Dukers N, Krol A, van Ameijden EJ, van Leeuwen R, Roos MT, de Wolf F, Coutinho RA, Keet IP.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Nov 1;19(3):254-9.

PMID:
9803967
18.

Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997.

van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chêne G, Dorrucci M, Muga R, Porter K, Prins M; CASCADE Collaboration in EuroCoord.

Gastroenterology. 2013 Apr;144(4):751-760.e2. doi: 10.1053/j.gastro.2012.12.026. Epub 2012 Dec 22.

PMID:
23266560
19.

Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?

Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE Collaboration).

J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):158-65.

PMID:
11588510
20.

Long-term HIV-1 infection without immunologic progression.

Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD.

AIDS. 1994 Aug;8(8):1123-8.

PMID:
7986410

Supplemental Content

Support Center